StockData
Cerenome, Inc. logo

Cerenome, Inc. (CNSY) stock

CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.63−0.08 (-11.82%)

Close on Nov 17, 2026Market cap $4.78MP/E –Yield –

Earnings

Cerenome's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$700.00K
-50.0% on a year earlier
EPS, Q3 FY2026
-$1.14
-$0.04 a year earlier
Latest guidance
Reaffirmed
Aug 14, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Cerenome's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 13, 2026after the close$700.00K-50.0%-$1.14Release
Q2 FY2026ended Jun 30, 2026Aug 14, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 15, 2026after the close$1.00M–-$1.05Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025after the close$1.40M–-$0.04Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025after the close$1.40M+9.5%-$0.01Release
Q1 FY2025ended Mar 31, 2025May 30, 2025after the close––-$1.19Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024after the close–––Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024after the close$1.28M-32.7%-$0.71Release
Q1 FY2024ended Mar 31, 2024May 15, 2024after the close$1.70M+236.0%-$0.75Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Cerenome's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
annualized run-rate of test ordersFY20261250–ReaffirmedAug 14, 2026
annualized test ordersFY202612501250RaisedMay 15, 2026
commercial payer coverage (covered lives)FY2026150–NewMar 12, 2026
covered livesFY2026150–LoweredMay 15, 2026

Guidance history

Every forecast Cerenome put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 14, 2026annualized run-rate of test ordersFY20261250Reaffirmed
May 15, 2026covered livesFY2026150Lowered
May 15, 2026annualized test ordersFY20261250Raised
Mar 12, 2026commercial payer coverage (covered lives)FY2026150New
Mar 12, 2026annualized test ordersFY20261250Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Cerenome filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. News
  4. News
  5. News
  6. Results
  7. Results
  8. News
  9. News
  10. News
  11. Results
  12. News
  13. News
  14. Update
  15. Results

See a number that looks wrong?